8-K: Zomedica CFO Scott Jordan Resigns, Transition Plan Initiated

Zomedica Corp. announces the resignation of Chief Financial Officer Scott Jordan, effective April 25, 2025, with Vice President of Finance and Corporate Controller Michael Zuehlke assuming operational responsibility for accounting and finance matters until a replacement is found.

Summary

• Zomedica Corp. announced the resignation of its Chief Financial Officer, Scott Jordan, effective April 25, 2025.
• Mr. Jordan is returning to his consulting firm, S. Jordan Associates.
• Zomedica and Mr. Jordan entered into a separation and release agreement.
• Under the agreement, Mr. Jordan will receive three months of his base annual salary and reimbursement for three months of COBRA coverage.
• The separation agreement includes a release of claims, confidentiality, and non-disparagement obligations.
• Michael Zuehlke, Vice President of Finance and Corporate Controller, will assume operational responsibility for accounting and finance matters until a new CFO is appointed.
• The company is actively seeking a replacement for the CFO position.

Sentiment

Score: 5

Explanation: The announcement is neutral, detailing a change in executive leadership. The impact on the company's performance will depend on the quality and speed of the CFO replacement.

Positives

• The company has a transition plan in place with Michael Zuehlke assuming CFO responsibilities on an interim basis, ensuring continuity in financial operations.
• The separation agreement includes standard protections for the company, such as confidentiality and non-disparagement clauses.

Negatives

• The resignation of the CFO creates uncertainty in the company's financial leadership.
• The company will incur costs associated with the CFO's separation package, including salary continuation and COBRA reimbursement.

Risks

• The search for a new CFO could be lengthy and disruptive.
• The interim CFO may not have the same level of experience or expertise as the departing CFO.
• There is a risk of potential knowledge gaps or operational inefficiencies during the transition period.

Future Outlook

The company is actively seeking a new CFO to fill the vacancy.

Industry Context

Executive turnover is a common occurrence in publicly traded companies, and the market will likely focus on the company's ability to quickly and effectively fill the CFO position with a qualified candidate.

Comparison to Industry Standards

• Executive compensation and separation packages are generally benchmarked against industry peers and company size.
• The terms of Scott Jordan's separation agreement appear to be standard for executive departures.
• Comparable companies in the animal health industry include IDEXX Laboratories and Zoetis, which have similar executive compensation structures.

Management Changes

Stakeholder Impact

• Shareholders may react to the news of the CFO's departure, depending on their confidence in the company's transition plan.
• Employees in the finance department may experience uncertainty during the transition period.
• Customers and suppliers are unlikely to be directly impacted by the CFO's departure.

Next Steps

• Zomedica will continue its search for a permanent CFO.
• Michael Zuehlke will continue to oversee accounting and finance matters on an interim basis.
• The company will likely announce the appointment of a new CFO in a future filing.

Key Dates

Keywords

CFO, resignation, Zomedica, Scott Jordan, Michael Zuehlke, separation agreement, financial officer, appointment, transition